Syntara (ASX:SNT) — Material Events
ASX:SNT · 11 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Syntara Advances Clinical Trials and Secures EMA Orphan Drug StatusHigh
Syntara advances clinical pipeline with key trials and regulatory milestones; $12.3M proforma cash at year-end
29 Jan 2026
·Quarterly Activity and Cash Flow Report
·85
Syntara Advances Clinical Trials with FDA Backing and $8M Capital BoostHigh
Syntara advances clinical trials with FDA support and $8M capital raise, extends cash runway to Q3 2027
27 July 2026
·Quarterly Activities and Cash Flow Report
·85
Syntara’s Amsulostat Shows Strong Phase 2a Results in Myelofibrosis TrialMedium
Syntara reports positive Phase 2a data for amsulostat in myelofibrosis, advancing clinical development
30 Sept 2025
·Clinical Trial Results
·85
Syntara’s Amsulostat Shows Durable Symptom Relief in Myelofibrosis Phase 2a TrialMedium
Syntara reports positive Phase 2a data for amsulostat in myelofibrosis treatment
30 Sept 2025
·Clinical Trial Results
·85
Syntara’s Amsulostat Shows Durable Benefits in Myelofibrosis Phase 2a TrialMedium
Syntara reports strong Phase 2a results for amsulostat in myelofibrosis, advances clinical pipeline, and maintains solid cash position
28 Oct 2025
·Quarterly Activity Report and Appendix 4C
·85
Syntara Advances Topical Scar Treatment SNT-9465 to Phase 1b After Promising Phase 1aMedium
Syntara advances topical anti-fibrotic SNT-9465 to Phase 1b after positive Phase 1a results
26 Nov 2025
·Media Release
·85
Garvan Institute Secures $3M Grant to Test Syntara’s Drug in Pancreatic Cancer TrialMedium
Syntara-backed Garvan Institute wins $3M MRFF grant for pancreatic cancer trials with amsulostat
21 Jan 2026
·Media Release
·85
Syntara Secures A$10 Million to Fuel Clinical Trials After FDA NodMedium
Syntara raises A$10 million to advance clinical trials and pipeline after positive FDA feedback
29 Apr 2026
·Capital Raising
·85
Syntara Reports Higher Loss on Lower Revenue; Advances Clinical Pipeline with FDA Support and $8.8M Capital RaiseMedium
Syntara reports higher loss on lower revenue; advances clinical pipeline with FDA support and $8.8M capital raise
27 Aug 2026
·Annual Report and Financial Results
·75
Syntara Launches $2M Share Plan at 15.6% Discount After $8M PlacementMedium
Syntara launches A$2 million Share Purchase Plan at A$0.027 per share following A$8 million placement
14 May 2026
·Capital Raising
·70
Syntara Raises $8.84M to Back Five Clinical Trial Readouts Through Share Purchase PlanMedium
Syntara completes $0.84M Share Purchase Plan, total raise $8.84M to fund clinical trials and development
10 June 2026
·Capital Raising
·70
No articles in this tier for the last 12 months.
Market Mentions
6
- appeared in market wrap coverage
These are market wrap articles where Syntara (ASX:SNT) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Healthcare Wrap - Week 24 (8 June -> 12 June) 2026
13 June 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026